LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 140 COAGULATION (HEMAT.)

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
080 FIBRINOGEN			CLIA TEST ID #: 825		EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-941	69	DIAG.STAGO	85	STA FIBRI		11	143.091	12.515	8.75	114.000	172.000
2025-941	73	ACL 8 TO E	87	HEMOSIL-C		10	141.600	7.459	5.27	113.000	170.000
2025-941	79	CS-2500	67	DADE		15	118.533	8.594	7.25	95.000	142.000
2025-942	69	DIAG.STAGO	85	STA FIBRI		11	273.000	12.771	4.68	218.000	328.000
2025-942	73	ACL 8 TO E	87	HEMOSIL-C		10	280.700	10.593	3.77	225.000	337.000
2025-942	79	CS-2500	67	DADE		15	235.800	13.693	5.81	189.000	283.000
2025-943	69	DIAG.STAGO	85	STA FIBRI		11	282.182	14.671	5.20	226.000	339.000
2025-943	73	ACL 8 TO E	87	HEMOSIL-C		10	297.100	20.102	6.77	238.000	357.000
2025-943	79	CS-2500	67	DADE		15	233.800	13.328	5.70	187.000	281.000
2025-944	69	DIAG.STAGO	85	STA FIBRI		11	272.455	21.475	7.88	218.000	327.000
2025-944	73	ACL 8 TO E	87	HEMOSIL-C		10	283.600	8.237	2.90	227.000	340.000
2025-944	79	CS-2500	67	DADE		15	234.667	15.990	6.81	188.000	282.000
2025-945	69	DIAG.STAGO	85	STA FIBRI		11	494.909	28.449	5.75	396.000	594.000
2025-945	73	ACL 8 TO E	87	HEMOSIL-C		10	510.300	47.827	9.37	408.000	612.000
2025-945	79	CS-2500	67	DADE		15	418.067	24.885	5.95	334.000	502.000
081 PART.THROM. TIME-PTT			CLIA TEST ID #: 835		EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-941	62	DADE SYS.	35	DADE ACTIN		61	28.610	0.831	2.91	24.300	32.900
2025-941	69	DIAG.STAGO	49	STA-PTT		23	34.123	1.309	3.84	29.000	39.200
2025-941	73	ACL 8 TO E	56	PTT-HEMO		27	29.156	0.338	1.16	24.800	33.500
2025-941	76	STAGO STAR	49	STA-PTT		20	31.783	1.811	5.70	27.000	36.600
2025-941	76	STAGO STAR	49	STA-PTT		20	32.816	1.525	4.65	27.900	37.700
2025-941	79	CS-2500	35	DADE ACTIN		16	29.881	0.807	2.70	25.400	34.400
2025-942	62	DADE SYS.	35	DADE ACTIN		61	38.557	1.455	3.77	32.800	44.300

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 2 (24)
DATE : 1/23/2026
TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY SUB: 70 GENERAL GRP: 140 COAGULATION (HEMAT.)

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-942	69	DIAG.STAGO	49	STA-PTT		23	41.377	1.931	4.67	35.200	47.600
2025-942	73	ACL 8 TO E	56	PTT-HEMO		27	38.619	1.506	3.90	32.800	44.400
2025-942	76	STAGO STAR	49	STA-PTT		20	40.370	2.368	5.86	34.300	46.400
2025-942	76	STAGO STAR	49	STA-PTT		20	42.850	3.634	8.48	36.400	49.300
2025-942	79	CS-2500	35	DADE ACTIN		16	40.663	1.582	3.89	34.600	46.800

081 PART.THROM. TIME-PTT CLIA TEST ID #: 835 EVALUATION CRITERIA: TARGET VALUE 15 %

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-943	62	DADE SYS.	35	DADE ACTIN		61	29.277	0.832	2.84	24.900	33.700
2025-943	69	DIAG.STAGO	49	STA-PTT		23	30.632	1.244	4.06	26.000	35.200
2025-943	73	ACL 8 TO E	56	PTT-HEMO		27	28.578	0.425	1.49	24.300	32.900
2025-943	76	STAGO STAR	49	STA-PTT		20	31.033	1.776	5.72	26.400	35.700
2025-943	76	STAGO STAR	49	STA-PTT		20	29.915	1.649	5.51	25.400	34.400
2025-943	79	CS-2500	35	DADE ACTIN		16	30.244	0.678	2.24	25.700	34.800
2025-944	62	DADE SYS.	35	DADE ACTIN		61	42.218	1.655	3.92	35.900	48.600
2025-944	69	DIAG.STAGO	49	STA-PTT		23	44.159	1.666	3.77	37.500	50.800
2025-944	73	ACL 8 TO E	56	PTT-HEMO		27	43.907	0.768	1.75	37.300	50.500
2025-944	76	STAGO STAR	49	STA-PTT		20	46.433	3.549	7.64	39.500	53.400
2025-944	76	STAGO STAR	49	STA-PTT		20	43.920	3.125	7.11	37.300	50.500
2025-944	79	CS-2500	35	DADE ACTIN		16	44.569	1.395	3.13	37.900	51.300
2025-945	62	DADE SYS.	35	DADE ACTIN		61	26.337	0.799	3.03	22.400	30.300
2025-945	69	DIAG.STAGO	49	STA-PTT		23	28.723	1.033	3.60	24.400	33.000
2025-945	73	ACL 8 TO E	56	PTT-HEMO		27	36.274	0.971	2.68	30.800	41.700
2025-945	76	STAGO STAR	49	STA-PTT		20	28.765	1.449	5.04	24.500	33.100
2025-945	76	STAGO STAR	49	STA-PTT		20	26.850	1.406	5.24	22.800	30.900
2025-945	79	CS-2500	35	DADE ACTIN		16	26.813	0.567	2.11	22.800	30.800

082 PROTHROMBIN TIME(PT) CLIA TEST ID #: 845

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-941	62	DADE SYS.	33	DADE INNOV		62	12.406	0.369	2.97	10.500	14.300
2025-941	69	DIAG.STAGO	44	STA NEO CI		13	15.650	0.284	1.82	13.300	18.000
2025-941	73	ACL 8 TO E	41	HEMOSIL RE		25	13.516	0.320	2.36	11.500	15.500

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 3 (24)
DATE : 1/23/2026
TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 140 COAGULATION (HEMAT.)

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-941	76	STAGO STAR	44	STA NEO CI		13	15.531	0.530	3.41	13.200	17.900
2025-941	79	CS-2500	33	DADE INNOV		17	12.859	0.203	1.58	10.900	14.800

082 PROTHROMBIN TIME(PT)   CLIA TEST ID #: 845   EVALUATION CRITERIA: TARGET VALUE 15 %

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-942	62	DADE SYS.	33	DADE INNOV		62	19.248	0.710	3.69	16.400	22.100
2025-942	69	DIAG.STAGO	44	STA NEO CI		13	26.117	0.564	2.16	22.200	30.000
2025-942	73	ACL 8 TO E	41	HEMOSIL RE		25	21.516	0.612	2.84	18.300	24.700
2025-942	76	STAGO STAR	44	STA NEO CI		13	27.515	1.024	3.72	23.400	31.600
2025-942	79	CS-2500	33	DADE INNOV		17	19.571	0.453	2.32	16.600	22.500
2025-943	62	DADE SYS.	33	DADE INNOV		62	10.231	0.245	2.40	8.700	11.800
2025-943	69	DIAG.STAGO	44	STA NEO CI		13	13.591	0.211	1.55	11.600	15.600
2025-943	73	ACL 8 TO E	41	HEMOSIL RE		25	11.288	0.280	2.48	9.600	13.000
2025-943	76	STAGO STAR	44	STA NEO CI		13	13.054	0.337	2.58	11.100	15.000
2025-943	79	CS-2500	33	DADE INNOV		17	10.788	0.305	2.82	9.200	12.400
2025-944	62	DADE SYS.	33	DADE INNOV		62	26.560	1.256	4.73	22.600	30.500
2025-944	69	DIAG.STAGO	44	STA NEO CI		13	35.450	1.540	4.34	30.100	40.800
2025-944	73	ACL 8 TO E	41	HEMOSIL RE		25	30.940	1.079	3.49	26.300	35.600
2025-944	76	STAGO STAR	44	STA NEO CI		13	37.246	1.336	3.59	31.700	42.800
2025-944	79	CS-2500	33	DADE INNOV		17	27.041	0.640	2.37	23.000	31.100
2025-945	62	DADE SYS.	33	DADE INNOV		62	11.139	0.263	2.36	9.500	12.800
2025-945	69	DIAG.STAGO	44	STA NEO CI		13	14.175	0.339	2.39	12.000	16.300
2025-945	73	ACL 8 TO E	41	HEMOSIL RE		25	11.472	0.332	2.89	9.800	13.200
2025-945	76	STAGO STAR	44	STA NEO CI		13	13.715	0.485	3.54	11.700	15.800
2025-945	79	CS-2500	33	DADE INNOV		17	11.688	0.358	3.06	9.900	13.400

1/23/2026   PROFICIENCY TESTING SERVICE   PAGE : 4 (24)
                         LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
                  DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPE: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 100 HEMA. CELL IDENTIFI.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
	072 HEMA. CELL IDENTIFI.										
2025-891					005 005		017 - MONOCYTE	924	4	919	0
2025-891					005 005		004 - METAMYELOC	924	1	919	0
2025-891					005 005		005 - BAND (STAB	924	919	919	100
2025-892					020 020		013 - LYMPHOCYTE	924	1	923	0
2025-892					020 020		020 - GIANT PLA	924	923	923	100
2025-893					007 007		012 - MAST CELL,	924	1	923	0
2025-893					007 007		007 - BASOPHIL,	924	923	923	100
2025-894					046 046		030 - ERYTHROCYT	984	6	900	0
2025-894					046 046		033 - POLYCHROMA	984	29	900	0
2025-894					046 046		036 - BASOPHILIC	984	17	900	0
2025-894					046 046		046 - ERYTHROCYT	984	900	900	100
2025-894					046 046		048 - ERYTHROCYT	984	1	900	0
2025-894					046 046		050 - OVALOCYTE	984	9	900	0
2025-894					046 046		052 - SPHEROCYTE	984	20	900	0
2025-894					046 046		071 - Poikilo.	984	2	900	0
2025-895					006 006		011 - HYPERSEGME	1756	4	1711	0
2025-895					006 006		017 - MONOCYTE	1756	2	1711	0
2025-895					006 006		026 - LEUKOCYTE	1756	1	1711	0
2025-895					006 006		004 - METAMYELOC	1756	1	1711	0
2025-895					006 006		005 - BAND (STAB	1756	35	1711	0
2025-895					006 006		006 - SEGMENTED	1756	789	1711	100
2025-895					006 006		007 - BASOPHIL,	1756	1	1711	0
2025-895					029 029		023 - ALDER ANOM	1756	1	1711	0

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 5 (24)
DATE : 1/23/2026
TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPE: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 100 HEMA. CELL IDENTIFI.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-895					029 029		029 - TOXIC GRAN	1756	922	1711	100

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 137 RETICULOCYTE COUNT

ANALYTE SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
149 RETICULOCYTE COUNT			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}						
2025-921	24	Unicel DxH			13	4.125	0.298	7.21	3.100	5.200
2025-921	25	SYSMEX XN			36	1.489	0.524	35.18	0	3.100
2025-922	24	Unicel DxH			13	1.008	0.202	20.02	0.400	1.600
2025-922	25	SYSMEX XN			36	0.617	0.073	11.78	0.400	0.800
2025-923	24	Unicel DxH			13	8.433	0.563	6.68	6.300	10.500
2025-923	25	SYSMEX XN			36	2.594	1.511	58.24	0	7.100
2025-924	24	Unicel DxH			13	0.992	0.194	19.55	0.400	1.600
2025-924	25	SYSMEX XN			36	0.646	0.060	9.32	0.500	0.800
2025-925	24	Unicel DxH			13	3.992	0.320	8.02	3.000	5.000
2025-925	25	SYSMEX XN			36	1.492	0.558	37.41	0	3.200

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 138 SED. RATE (ESR)

ANALYTE SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
153 SED. RATE (ESR)				EVALUATION CRITERIA: TARGET VALUE 3 SD OR 35 % {GREATER}						
2025-931	4	SEDIPLAST			650	6.580	1.972	29.96	1.000	12.000

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 138 SED. RATE (ESR)

ANALYTE SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-931	10	SEDI RATE			60	7.483	1.887	25.22	2.000	13.000
2025-931	11	SEDIMAT-15			43	7.808	4.691	60.08	0	22.000
2025-931	14	GLOBAL SC.			10	8.800	1.400	15.91	5.000	13.000
2025-931	19	MINI CUBE			52	13.833	1.934	13.98	8.000	20.000

153 SED. RATE (ESR)   CLIA TEST ID #: 0   EVALUATION CRITERIA: TARGET VALUE 3 SD OR 35 % {GREATER}

ANALYTE SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-932	4	SEDIPLAST			650	36.064	6.008	16.66	18.000	54.000
2025-932	10	SEDI RATE			60	36.339	6.915	19.03	16.000	57.000
2025-932	11	SEDIMAT-15			43	109.680	12.979	11.83	71.000	149.000
2025-932	14	GLOBAL SC.			10	44.400	10.394	23.41	13.000	76.000
2025-932	19	MINI CUBE			52	48.097	9.793	20.36	19.000	77.000
2025-933	4	SEDIPLAST			650	6.568	1.732	26.37	1.000	12.000
2025-933	10	SEDI RATE			60	8.362	2.295	27.44	1.000	15.000
2025-933	11	SEDIMAT-15			43	8.346	4.875	58.41	0	23.000
2025-933	14	GLOBAL SC.			10	8.500	1.025	12.06	5.000	12.000
2025-933	19	MINI CUBE			52	13.567	1.359	10.01	9.000	18.000
2025-934	4	SEDIPLAST			650	35.787	5.701	15.93	19.000	53.000
2025-934	10	SEDI RATE			60	36.850	7.330	19.89	15.000	59.000
2025-934	11	SEDIMAT-15			43	109.840	11.149	10.15	71.000	148.000
2025-934	14	GLOBAL SC.			10	40.500	6.454	15.94	21.000	60.000
2025-934	19	MINI CUBE			52	47.667	10.361	21.74	17.000	79.000
2025-935	4	SEDIPLAST			650	6.538	1.676	25.64	2.000	12.000
2025-935	10	SEDI RATE			60	7.271	1.505	20.70	3.000	12.000
2025-935	11	SEDIMAT-15			43	9.077	5.298	58.37	0	25.000
2025-935	14	GLOBAL SC.			10	9.500	2.062	21.70	3.000	16.000
2025-935	19	MINI CUBE			52	13.867	1.477	10.65	9.000	19.000

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 7 (24)
DATE : 1/23/2026
TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH

172 DIFF. WBC FOR 5 PAR.   CLIA TEST ID #: 770   EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025911X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	34	75.100	0.983	1.31	56.300	93.900
2025911X	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	33	71.848	0.946	1.32	53.900	89.800
2025911X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	34	19.336	0.564	2.92	14.500	24.200
2025911X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	33	18.630	0.726	3.89	14.000	23.300
2025911X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	34	1.674	0.437	26.10	0	3.700
2025911X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	33	1.785	0.411	23.04	0	3.800
2025911X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	34	3.826	0.862	22.54	1.800	5.800
2025911X	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	33	3.718	0.688	18.50	1.700	5.700
2025911X	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	34	80.997	1.389	1.72	60.700	101.200
2025911X	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	33	4.013	0.041	1.03	2.000	6.000
2025911X	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	14	73.107	0.495	0.68	54.800	91.400
2025911X	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	14	14.679	0.378	2.58	11.000	18.300
2025911X	3	ADVIA 120	3	MONOCYTE	9	ADVIA-120	14	8.286	0.360	4.35	6.200	10.400
2025911X	3	ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	14	1.157	0.129	11.18	0	3.200
2025911X	3	ADVIA 120	5	BASOPHIL	9	ADVIA-120	14	0.371	0.133	35.87	0	2.400
2025911X	3	ADVIA 120	6	LUC	9	ADVIA-120	14	2.379	0.632	26.55	0.400	4.400
2025911X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	109	80.836	1.495	1.85	60.600	101.000
2025911X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	109	11.092	1.360	12.26	8.300	13.900
2025911X	7	DXH	3	MONOCYTE	36	BC DXH 500	109	0.553	0.294	53.05	0	2.600
2025911X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	109	7.448	0.521	6.99	5.400	9.400
2025911X	7	DXH	5	BASOPHIL	36	BC DXH 500	109	0.078	0.069	89.18	0	2.100
2025912X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	34	52.741	1.682	3.19	39.600	65.900
2025912X	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	33	51.500	1.361	2.64	38.600	64.400
2025912X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	35	39.253	1.807	4.60	29.400	49.100
2025912X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	33	37.956	1.193	3.14	28.500	47.400
2025912X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	34	2.103	0.536	25.50	0.100	4.100
2025912X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	33	2.039	0.566	27.74	0.000	4.000
2025912X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	33	5.873	0.825	14.06	3.900	7.900

1/23/2026   PROFICIENCY TESTING SERVICE   PAGE : 8 (24)
LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025912X	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	33	5.818	0.793	13.63	3.800	7.800
2025912X	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	34	56.082	1.245	2.22	42.100	70.100
2025912X	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	33	2.800	0.056	2.00	0.800	4.800
2025912X	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	14	45.257	1.236	2.73	33.900	56.600
2025912X	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	14	33.293	1.214	3.65	25.000	41.600
2025912X	3	ADVIA 120	3	MONOCYTE	9	ADVIA-120	14	14.714	0.784	5.33	11.000	18.400
2025912X	3	ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	14	0.907	0.191	21.03	0	2.900
2025912X	3	ADVIA 120	5	BASOPHIL	9	ADVIA-120	14	0.993	0.401	40.37	0	3.000
2025912X	3	ADVIA 120	6	LUC	9	ADVIA-120	14	5.254	0.702	13.37	3.300	7.300
2025912X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	109	47.730	3.578	7.50	35.800	59.700
2025912X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	109	37.448	3.659	9.77	28.100	46.800
2025912X	7	DXH	3	MONOCYTE	36	BC DXH 500	110	0.420	0.209	49.79	0	2.400
2025912X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	110	13.976	2.248	16.09	10.500	17.500
2025912X	7	DXH	5	BASOPHIL	36	BC DXH 500	107	0.149	0.100	66.83	0	2.100

172 DIFF. WBC FOR 5 PAR.   CLIA TEST ID #: 770   EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025913X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	34	57.947	1.294	2.23	43.500	72.400
2025913X	2	ACT PENTRA	1	NEUTROPHIL	24	ABX PENTRA	33	56.361	1.524	2.70	42.300	70.500
2025913X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	34	36.879	1.142	3.10	27.700	46.100
2025913X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	33	35.321	1.361	3.85	26.500	44.200
2025913X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	34	1.897	0.348	18.33	0	3.900
2025913X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	33	1.958	0.403	20.59	0.000	4.000
2025913X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	34	3.235	0.758	23.44	1.200	5.200
2025913X	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	33	3.303	0.542	16.41	1.300	5.300
2025913X	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	34	60.406	0.880	1.46	45.300	75.500
2025913X	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	33	3.013	0.034	1.11	1.000	5.000
2025913X	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	14	63.229	0.763	1.21	47.400	79.000
2025913X	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	14	23.279	0.576	2.47	17.500	29.100
2025913X	3	ADVIA 120	3	MONOCYTE	9	ADVIA-120	14	8.186	0.804	9.83	6.100	10.200
2025913X	3	ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	14	1.207	0.183	15.17	0	3.200
2025913X	3	ADVIA 120	5	BASOPHIL	9	ADVIA-120	14	0.971	0.279	28.70	0	3.000
2025913X	3	ADVIA 120	6	LUC	9	ADVIA-120	14	3.692	0.457	12.36	1.700	5.700

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 9 (24)
DATE : 1/23/2026
TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025913X	7	DXH	1	NEUTROPHIL	36 BC DXH 500	109	69.070	2.141	3.10	51.800	86.300
2025913X	7	DXH	2	LYMPHOCYTE	36 BC DXH 500	109	24.744	2.044	8.26	18.600	30.900
2025913X	7	DXH	3	MONOCYTE	36 BC DXH 500	109	1.091	0.508	46.62	0	3.100
2025913X	7	DXH	4	EOSINOPHIL	36 BC DXH 500	108	4.869	0.655	13.46	2.900	6.900
2025913X	7	DXH	5	BASOPHIL	36 BC DXH 500	110	0.210	0.251	119.54	0	2.200

172 DIFF. WBC FOR 5 PAR.   CLIA TEST ID #: 770   EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025914X	2	ACT PENTRA	1	NEUTROPHIL	15 COUL ACT 5	34	75.064	0.832	1.11	56.300	93.800
2025914X	2	ACT PENTRA	1	NEUTROPHIL	24 ABX PENTRA	33	71.945	0.957	1.33	54.000	89.900
2025914X	2	ACT PENTRA	2	LYMPHOCYTE	15 COUL ACT 5	34	19.436	0.683	3.51	14.600	24.300
2025914X	2	ACT PENTRA	2	LYMPHOCYTE	24 ABX PENTRA	33	18.570	0.747	4.02	13.900	23.200
2025914X	2	ACT PENTRA	3	MONOCYTE	15 COUL ACT 5	34	1.591	0.312	19.60	0	3.600
2025914X	2	ACT PENTRA	3	MONOCYTE	24 ABX PENTRA	34	1.759	0.362	20.60	0	3.800
2025914X	2	ACT PENTRA	4	EOSINOPHIL	15 COUL ACT 5	34	3.782	0.854	22.58	1.800	5.800
2025914X	2	ACT PENTRA	4	EOSINOPHIL	24 ABX PENTRA	33	3.718	0.767	20.64	1.700	5.700
2025914X	2	ACT PENTRA	5	BASOPHIL	15 COUL ACT 5	34	80.824	1.167	1.44	60.600	101.000
2025914X	2	ACT PENTRA	5	BASOPHIL	24 ABX PENTRA	33	4.009	0.067	1.67	2.000	6.000
2025914X	3	ADVIA 120	1	NEUTROPHIL	9 ADVIA-120	14	72.879	0.658	0.90	54.700	91.100
2025914X	3	ADVIA 120	2	LYMPHOCYTE	9 ADVIA-120	14	14.707	0.310	2.11	11.000	18.400
2025914X	3	ADVIA 120	3	MONOCYTE	9 ADVIA-120	14	8.486	0.439	5.17	6.400	10.600
2025914X	3	ADVIA 120	4	EOSINOPHIL	9 ADVIA-120	14	1.236	0.163	13.19	0	3.200
2025914X	3	ADVIA 120	5	BASOPHIL	9 ADVIA-120	14	0.407	0.122	30.03	0	2.400
2025914X	3	ADVIA 120	6	LUC	9 ADVIA-120	14	2.454	0.298	12.13	0.500	4.500
2025914X	7	DXH	1	NEUTROPHIL	36 BC DXH 500	109	80.956	1.199	1.48	60.700	101.200
2025914X	7	DXH	2	LYMPHOCYTE	36 BC DXH 500	109	10.855	1.222	11.25	8.100	13.600
2025914X	7	DXH	3	MONOCYTE	36 BC DXH 500	109	0.534	0.304	56.79	0	2.500
2025914X	7	DXH	4	EOSINOPHIL	36 BC DXH 500	109	7.535	0.709	9.41	5.500	9.500
2025914X	7	DXH	5	BASOPHIL	36 BC DXH 500	109	0.061	0.063	103.67	0	2.100
2025915X	2	ACT PENTRA	1	NEUTROPHIL	15 COUL ACT 5	34	52.600	1.609	3.06	39.500	65.800
2025915X	2	ACT PENTRA	1	NEUTROPHIL	24 ABX PENTRA	33	51.366	1.453	2.83	38.500	64.200

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 10 (24)
DATE : 1/23/2026
TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025915X	2	ACT PENTRA	2	LYMPHOCYTE	15	COUL ACT 5	34	39.315	1.041	2.65	29.500	49.100
2025915X	2	ACT PENTRA	2	LYMPHOCYTE	24	ABX PENTRA	33	37.728	1.443	3.82	28.300	47.200
2025915X	2	ACT PENTRA	3	MONOCYTE	15	COUL ACT 5	34	2.030	0.521	25.65	0.000	4.000
2025915X	2	ACT PENTRA	3	MONOCYTE	24	ABX PENTRA	33	1.997	0.516	25.82	0.000	4.000
2025915X	2	ACT PENTRA	4	EOSINOPHIL	15	COUL ACT 5	34	5.927	0.811	13.69	3.900	7.900
2025915X	2	ACT PENTRA	4	EOSINOPHIL	24	ABX PENTRA	33	6.082	0.845	13.89	4.100	8.100
2025915X	2	ACT PENTRA	5	BASOPHIL	15	COUL ACT 5	34	55.968	1.300	2.32	42.000	70.000
2025915X	2	ACT PENTRA	5	BASOPHIL	24	ABX PENTRA	33	2.797	0.047	1.67	0.800	4.800
2025915X	3	ADVIA 120	1	NEUTROPHIL	9	ADVIA-120	14	45.471	1.504	3.31	34.100	56.800
2025915X	3	ADVIA 120	2	LYMPHOCYTE	9	ADVIA-120	14	33.250	0.800	2.41	24.900	41.600
2025915X	3	ADVIA 120	3	MONOCYTE	9	ADVIA-120	14	14.521	0.868	5.98	10.900	18.200
2025915X	3	ADVIA 120	4	EOSINOPHIL	9	ADVIA-120	15	0.840	0.239	28.44	0	2.800
2025915X	3	ADVIA 120	5	BASOPHIL	9	ADVIA-120	13	0.708	0.173	24.45	0	2.700
2025915X	3	ADVIA 120	6	LUC	9	ADVIA-120	14	5.438	0.605	11.12	3.400	7.400
2025915X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	109	47.444	2.932	6.18	35.600	59.300
2025915X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	110	37.739	3.586	9.50	28.300	47.200
2025915X	7	DXH	3	MONOCYTE	36	BC DXH 500	108	0.465	0.243	52.26	0	2.500
2025915X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	109	14.399	1.675	11.63	10.800	18.000
2025915X	7	DXH	5	BASOPHIL	36	BC DXH 500	109	0.133	0.087	65.53	0	2.100

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 128 DIFF 3 PARAMETER INS

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
186 DIFF 3 PARAMETER INS			CLIA TEST ID #: 770		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2025911Z	8	3ST	1	Lymphocyte	1	KX 21/X300	13	61.758	0.818	1.32	46.300	77.200

1/23/2026   PROFICIENCY TESTING SERVICE   PAGE : 11 (24)
                             LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
                           DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:53

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 128 DIFF 3 PARAMETER INS

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025911Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	14	61.050	1.731	2.83	45.800	76.300
2025911Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	13	14.550	0.589	4.05	10.900	18.200
2025911Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	14	10.686	0.795	7.44	8.000	13.400
2025911Z	8	3ST	3	Neutrophil	1	KX 21/X300	13	23.717	0.732	3.09	17.800	29.600
2025911Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	14	28.250	1.913	6.77	21.200	35.300

186 DIFF 3 PARAMETER INS   CLIA TEST ID #: 770   EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}

SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025912Z	8	3ST	1	Lymphocyte	1	KX 21/X300	13	11.217	1.573	14.02	8.400	14.000
2025912Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	14	13.638	0.909	6.67	10.200	17.000
2025912Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	13	18.817	1.054	5.60	14.100	23.500
2025912Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	14	11.814	1.504	12.73	8.900	14.800
2025912Z	8	3ST	3	Neutrophil	1	KX 21/X300	13	69.992	1.106	1.58	52.500	87.500
2025912Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	14	74.762	1.832	2.45	56.100	93.500
2025913Z	8	3ST	1	Lymphocyte	1	KX 21/X300	13	31.917	0.806	2.53	23.900	39.900
2025913Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	14	32.786	1.815	5.54	24.600	41.000
2025913Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	13	16.675	0.656	3.93	12.500	20.800
2025913Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	14	11.271	1.297	11.51	8.500	14.100
2025913Z	8	3ST	3	Neutrophil	1	KX 21/X300	13	51.408	1.069	2.08	38.600	64.300
2025913Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	14	55.957	2.514	4.49	42.000	69.900
2025914Z	8	3ST	1	Lymphocyte	1	KX 21/X300	13	62.175	0.736	1.18	46.600	77.700
2025914Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	14	60.836	1.883	3.10	45.600	76.000
2025914Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	13	14.773	0.600	4.06	11.100	18.500
2025914Z	8	3ST	2	Mix M/E/Ba	3	ABBOTT C-D	14	10.793	0.656	6.08	8.100	13.500
2025914Z	8	3ST	3	Neutrophil	1	KX 21/X300	13	23.058	0.696	3.02	17.300	28.800
2025914Z	8	3ST	3	Neutrophil	3	ABBOTT C-D	14	28.823	1.032	3.58	21.600	36.000
2025915Z	8	3ST	1	Lymphocyte	1	KX 21/X300	13	11.892	1.392	11.70	8.900	14.900
2025915Z	8	3ST	1	Lymphocyte	3	ABBOTT C-D	14	14.592	3.070	21.04	10.900	18.200
2025915Z	8	3ST	2	Mix M/E/Ba	1	KX 21/X300	13	18.991	1.766	9.30	14.200	23.700

1/23/2026
PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 12 (24)
DATE : 1/23/2026
TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 128 DIFF 3 PARAMETER INS

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025915Z	8	3ST	2	Mix M/E/Ba	3 ABBOTT C-D	14	12.186	1.584	13.00	9.100	15.200
2025915Z	8	3ST	3	Neutrophil	1 KX 21/X300	13	69.000	1.538	2.23	51.800	86.300
2025915Z	8	3ST	3	Neutrophil	3 ABBOTT C-D	14	73.108	3.958	5.41	54.800	91.400

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 132 COMP BLOOD COUNT NEW

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
549 RED CELL COUNT (RBC)			CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 4 %						
2025-911	2	ACT PENTRA	125	COULTER AC		33	5.110	0.089	1.75	4.910	5.310
2025-911	2	ACT PENTRA	130	ABX PENTRA		33	5.124	0.070	1.36	4.920	5.330
2025-911	3	ADVIA 120	116	ADVIA-120		14	5.532	0.107	1.94	5.310	5.750
2025-911	7	DXH500 Ser	149	BC DXH 500		109	5.206	0.087	1.67	5.000	5.410
2025-911	8	3 ST	84	ABBOTT C-D		14	5.906	0.128	2.17	5.670	6.140
2025-911	8	3 ST	138	SY KX-21N		10	5.888	0.072	1.23	5.650	6.120
2025-912	2	ACT PENTRA	125	COULTER AC		33	2.347	0.051	2.19	2.250	2.440
2025-912	2	ACT PENTRA	130	ABX PENTRA		33	2.357	0.056	2.39	2.260	2.450
2025-912	3	ADVIA 120	116	ADVIA-120		14	2.062	0.031	1.52	1.980	2.140
2025-912	7	DXH500 Ser	149	BC DXH 500		109	2.366	0.037	1.58	2.270	2.460
2025-912	8	3 ST	84	ABBOTT C-D		14	2.398	0.057	2.36	2.300	2.490
2025-912	8	3 ST	138	SY KX-21N		10	2.360	0.033	1.38	2.270	2.450
2025-913	2	ACT PENTRA	125	COULTER AC		33	4.542	0.082	1.80	4.360	4.720
2025-913	2	ACT PENTRA	130	ABX PENTRA		33	4.588	0.076	1.66	4.400	4.770
2025-913	3	ADVIA 120	116	ADVIA-120		14	4.362	0.051	1.17	4.190	4.540
2025-913	7	DXH500 Ser	149	BC DXH 500		109	4.723	0.075	1.59	4.530	4.910
2025-913	8	3 ST	84	ABBOTT C-D		14	4.077	0.055	1.36	3.910	4.240
2025-913	8	3 ST	138	SY KX-21N		10	3.993	0.060	1.50	3.830	4.150

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 132 COMP BLOOD COUNT NEW

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
549 RED CELL COUNT (RBC)			CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 4 %						
2025-914	2	ACT PENTRA	125	COULTER AC		33	5.103	0.065	1.28	4.900	5.310
2025-914	2	ACT PENTRA	130	ABX PENTRA		33	5.129	0.076	1.49	4.920	5.330
2025-914	3	ADVIA 120	116	ADVIA-120		14	5.538	0.073	1.31	5.320	5.760
2025-914	7	DXH500 Ser	149	BC DXH 500		109	5.187	0.071	1.38	4.980	5.390
2025-914	8	3 ST	84	ABBOTT C-D		14	5.883	0.134	2.28	5.650	6.120
2025-914	8	3 ST	138	SY KX-21N		10	5.886	0.079	1.34	5.650	6.120
2025-915	2	ACT PENTRA	125	COULTER AC		33	2.352	0.056	2.38	2.260	2.450
2025-915	2	ACT PENTRA	130	ABX PENTRA		33	2.358	0.051	2.15	2.260	2.450
2025-915	3	ADVIA 120	116	ADVIA-120		14	2.065	0.026	1.26	1.980	2.150
2025-915	7	DXH500 Ser	149	BC DXH 500		109	2.371	0.040	1.71	2.280	2.470
2025-915	8	3 ST	84	ABBOTT C-D		14	2.387	0.036	1.53	2.290	2.480
2025-915	8	3 ST	138	SY KX-21N		10	2.361	0.025	1.08	2.270	2.460
550 HEMATOCRIT (HCT)			CLIA TEST ID #: 785								
2025-911	2	ACT PENTRA	125	COULTER AC		33	47.115	0.972	2.06	45.200	49.000
2025-911	2	ACT PENTRA	130	ABX PENTRA		33	46.782	0.913	1.95	44.900	48.700
2025-911	3	ADVIA 120	116	ADVIA-120		14	46.829	1.162	2.48	45.000	48.700
2025-911	7	DXH500 Ser	149	BC DXH 500		109	50.081	1.076	2.15	48.100	52.100
2025-911	8	3 ST	84	ABBOTT C-D		14	54.271	2.695	4.97	52.100	56.400
2025-911	8	3 ST	138	SY KX-21N		10	53.200	0.943	1.77	51.100	55.300
2025-912	2	ACT PENTRA	125	COULTER AC		33	19.456	0.338	1.74	18.700	20.200
2025-912	2	ACT PENTRA	130	ABX PENTRA		33	19.297	0.400	2.07	18.500	20.100
2025-912	3	ADVIA 120	116	ADVIA-120		14	15.529	0.375	2.41	14.900	16.100
2025-912	7	DXH500 Ser	149	BC DXH 500		109	18.949	0.371	1.96	18.200	19.700
2025-912	8	3 ST	84	ABBOTT C-D		14	18.062	0.387	2.14	17.300	18.800
2025-912	8	3 ST	138	SY KX-21N		10	17.830	0.335	1.88	17.100	18.500
2025-913	2	ACT PENTRA	125	COULTER AC		33	39.215	0.917	2.34	37.600	40.800

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 132 COMP BLOOD COUNT NEW

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-913	2	ACT PENTRA	130	ABX PENTRA		33	39.176	0.821	2.10	37.600	40.700
2025-913	3	ADVIA 120	116	ADVIA-120		14	35.307	0.578	1.64	33.900	36.700
2025-913	7	DXH500 Ser	149	BC DXH 500		109	41.800	0.838	2.00	40.100	43.500
2025-913	8	3 ST	84	ABBOTT C-D		14	34.229	1.394	4.07	32.900	35.600
2025-913	8	3 ST	138	SY KX-21N		10	32.710	0.549	1.68	31.400	34.000

550 HEMATOCRIT (HCT)   CLIA TEST ID #: 785   EVALUATION CRITERIA: TARGET VALUE 4 %

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-914	2	ACT PENTRA	125	COULTER AC		33	47.009	0.918	1.95	45.100	48.900
2025-914	2	ACT PENTRA	130	ABX PENTRA		33	46.770	0.940	2.01	44.900	48.600
2025-914	3	ADVIA 120	116	ADVIA-120		14	46.871	0.971	2.07	45.000	48.700
2025-914	7	DXH500 Ser	149	BC DXH 500		109	49.884	0.873	1.75	47.900	51.900
2025-914	8	3 ST	84	ABBOTT C-D		14	54.108	1.221	2.26	51.900	56.300
2025-914	8	3 ST	138	SY KX-21N		10	53.100	0.949	1.79	51.000	55.200
2025-915	2	ACT PENTRA	125	COULTER AC		33	19.412	0.386	1.99	18.600	20.200
2025-915	2	ACT PENTRA	130	ABX PENTRA		33	19.318	0.387	2.00	18.500	20.100
2025-915	3	ADVIA 120	116	ADVIA-120		14	15.536	0.350	2.25	14.900	16.200
2025-915	7	DXH500 Ser	149	BC DXH 500		109	19.013	0.374	1.97	18.300	19.800
2025-915	8	3 ST	84	ABBOTT C-D		14	17.838	0.850	4.76	17.100	18.600
2025-915	8	3 ST	138	SY KX-21N		10	17.810	0.327	1.84	17.100	18.500

551 HEMOGLOBIN (HGB)   CLIA TEST ID #: 795

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-911	2	ACT PENTRA	125	COULTER AC		33	16.255	0.257	1.58	15.600	16.900
2025-911	2	ACT PENTRA	130	ABX PENTRA		33	16.376	0.205	1.25	15.700	17.000
2025-911	3	ADVIA 120	116	ADVIA-120		14	17.221	0.426	2.48	16.500	17.900
2025-911	7	DXH500 Ser	149	BC DXH 500		109	17.356	0.227	1.31	16.700	18.000
2025-911	8	3 ST	84	ABBOTT C-D		14	18.443	0.638	3.46	17.700	19.200
2025-911	8	3 ST	138	SY KX-21N		10	18.210	0.207	1.14	17.500	18.900
2025-912	2	ACT PENTRA	125	COULTER AC		33	6.409	0.087	1.35	6.200	6.700
2025-912	2	ACT PENTRA	130	ABX PENTRA		33	6.436	0.112	1.75	6.200	6.700
2025-912	3	ADVIA 120	116	ADVIA-120		14	5.650	0.112	1.98	5.400	5.900

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 15 (24)
DATE : 1/23/2026
TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 132 COMP BLOOD COUNT NEW

ANALYTE SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-912	7	DXH500 Ser	149	BC DXH 500		109	6.389	0.084	1.31	6.100	6.600
2025-912	8	3 ST	84	ABBOTT C-D		14	6.443	0.145	2.25	6.200	6.700
2025-912	8	3 ST	138	SY KX-21N		10	6.190	0.130	2.10	5.900	6.400

551 HEMOGLOBIN (HGB)   CLIA TEST ID #: 795   EVALUATION CRITERIA: TARGET VALUE 4 %

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-913	2	ACT PENTRA	125	COULTER AC		33	13.555	0.172	1.27	13.000	14.100
2025-913	2	ACT PENTRA	130	ABX PENTRA		33	13.630	0.191	1.40	13.100	14.200
2025-913	3	ADVIA 120	116	ADVIA-120		14	12.943	0.164	1.26	12.400	13.500
2025-913	7	DXH500 Ser	149	BC DXH 500		109	14.531	0.223	1.53	13.900	15.100
2025-913	8	3 ST	84	ABBOTT C-D		14	12.129	0.317	2.62	11.600	12.600
2025-913	8	3 ST	138	SY KX-21N		10	11.900	0.110	0.92	11.400	12.400
2025-914	2	ACT PENTRA	125	COULTER AC		33	16.318	0.196	1.20	15.700	17.000
2025-914	2	ACT PENTRA	130	ABX PENTRA		33	16.418	0.214	1.30	15.800	17.100
2025-914	3	ADVIA 120	116	ADVIA-120		14	17.236	0.329	1.91	16.500	17.900
2025-914	7	DXH500 Ser	149	BC DXH 500		109	17.238	0.191	1.11	16.500	17.900
2025-914	8	3 ST	84	ABBOTT C-D		14	18.286	0.469	2.56	17.600	19.000
2025-914	8	3 ST	138	SY KX-21N		10	18.230	0.162	0.89	17.500	19.000
2025-915	2	ACT PENTRA	125	COULTER AC		33	6.433	0.080	1.25	6.200	6.700
2025-915	2	ACT PENTRA	130	ABX PENTRA		33	6.424	0.105	1.63	6.200	6.700
2025-915	3	ADVIA 120	116	ADVIA-120		14	5.700	0.113	1.99	5.500	5.900
2025-915	7	DXH500 Ser	149	BC DXH 500		109	6.401	0.098	1.53	6.100	6.700
2025-915	8	3 ST	84	ABBOTT C-D		14	6.446	0.187	2.89	6.200	6.700
2025-915	8	3 ST	138	SY KX-21N		10	6.150	0.136	2.21	5.900	6.400

552 WHITE CELL COUNT(WBC   CLIA TEST ID #: 805   EVALUATION CRITERIA: TARGET VALUE 10 %

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-911	2	ACT PENTRA	125	COULTER AC		33	18.958	0.547	2.88	17.100	20.900
2025-911	2	ACT PENTRA	130	ABX PENTRA		33	18.848	0.531	2.82	17.000	20.700
2025-911	3	ADVIA 120	116	ADVIA-120		14	16.629	0.538	3.23	15.000	18.300
2025-911	7	DXH500 Ser	149	BC DXH 500		109	17.940	0.425	2.37	16.100	19.700
2025-911	8	3 ST	84	ABBOTT C-D		14	20.929	0.827	3.95	18.800	23.000

1/23/2026   PROFICIENCY TESTING SERVICE   PAGE : 16 (24)
LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 132 COMP BLOOD COUNT NEW

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-911	8	3 ST	138	SY KX-21N		10	21.020	0.763	3.63	18.900	23.100

552 WHITE CELL COUNT(WBC   CLIA TEST ID #: 805   EVALUATION CRITERIA: TARGET VALUE 10 %

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-912	2	ACT PENTRA	125	COULTER AC		33	2.861	0.101	3.54	2.600	3.100
2025-912	2	ACT PENTRA	130	ABX PENTRA		33	2.873	0.093	3.24	2.600	3.200
2025-912	3	ADVIA 120	116	ADVIA-120		14	3.100	0.093	2.99	2.800	3.400
2025-912	7	DXH500 Ser	149	BC DXH 500		109	2.311	0.108	4.69	2.100	2.500
2025-912	8	3 ST	84	ABBOTT C-D		14	2.950	0.140	4.75	2.700	3.200
2025-912	8	3 ST	138	SY KX-21N		10	2.850	0.128	4.51	2.600	3.100
2025-913	2	ACT PENTRA	125	COULTER AC		33	8.497	0.224	2.63	7.600	9.300
2025-913	2	ACT PENTRA	130	ABX PENTRA		33	8.455	0.206	2.44	7.600	9.300
2025-913	3	ADVIA 120	116	ADVIA-120		14	7.893	0.271	3.44	7.100	8.700
2025-913	7	DXH500 Ser	149	BC DXH 500		109	7.304	0.234	3.20	6.600	8.000
2025-913	8	3 ST	84	ABBOTT C-D		14	7.979	0.343	4.29	7.200	8.800
2025-913	8	3 ST	138	SY KX-21N		10	8.130	0.355	4.37	7.300	8.900
2025-914	2	ACT PENTRA	125	COULTER AC		33	18.988	0.585	3.08	17.100	20.900
2025-914	2	ACT PENTRA	130	ABX PENTRA		33	18.861	0.523	2.77	17.000	20.700
2025-914	3	ADVIA 120	116	ADVIA-120		14	16.585	0.280	1.69	14.900	18.200
2025-914	7	DXH500 Ser	149	BC DXH 500		109	17.867	0.409	2.29	16.100	19.700
2025-914	8	3 ST	84	ABBOTT C-D		14	20.714	0.800	3.86	18.600	22.800
2025-914	8	3 ST	138	SY KX-21N		10	20.770	0.754	3.63	18.700	22.800
2025-915	2	ACT PENTRA	125	COULTER AC		33	2.861	0.085	2.97	2.600	3.100
2025-915	2	ACT PENTRA	130	ABX PENTRA		33	2.915	0.102	3.49	2.600	3.200
2025-915	3	ADVIA 120	116	ADVIA-120		14	3.150	0.050	1.59	2.800	3.500
2025-915	7	DXH500 Ser	149	BC DXH 500		109	2.332	0.103	4.40	2.100	2.600
2025-915	8	3 ST	84	ABBOTT C-D		14	2.962	0.133	4.50	2.700	3.300
2025-915	8	3 ST	138	SY KX-21N		10	2.860	0.174	6.10	2.600	3.100

1/23/2026
PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 17 (24)
DATE : 1/23/2026
TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 134 PLATELET COUNT NEW

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
553 PLATELET COUNT			CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %						
2025-911	2	ACT5 PENTR	73	COULTER AC		32	471.656	13.628	2.89	354.000	590.000
2025-911	2	ACT5 PENTR	78	ABX PENTRA		33	467.182	15.304	3.28	350.000	584.000
2025-911	3	ADVIA 120	64	ADVIA-120		14	452.571	31.359	6.93	339.000	566.000
2025-911	8	3 ST	31	ABBOTT C-D		14	360.500	43.367	12.03	270.000	451.000
2025-911	8	3 ST	84	KX21,300		10	395.100	40.756	10.32	296.000	494.000
2025-911	10	DxH	94	BC DXH 500		109	514.151	21.098	4.10	386.000	643.000
2025-912	2	ACT5 PENTR	73	COULTER AC		32	74.156	4.078	5.50	56.000	93.000
2025-912	2	ACT5 PENTR	78	ABX PENTRA		33	74.758	5.371	7.18	56.000	93.000
2025-912	3	ADVIA 120	64	ADVIA-120		14	56.000	6.000	10.71	42.000	70.000
2025-912	8	3 ST	31	ABBOTT C-D		14	66.786	6.624	9.92	50.000	83.000
2025-912	8	3 ST	84	KX21,300		10	71.100	5.752	8.09	53.000	89.000
2025-912	10	DxH	94	BC DXH 500		109	74.000	4.635	6.26	56.000	93.000
2025-913	2	ACT5 PENTR	73	COULTER AC		32	244.375	8.898	3.64	183.000	305.000
2025-913	2	ACT5 PENTR	78	ABX PENTRA		33	245.212	10.135	4.13	184.000	307.000
2025-913	3	ADVIA 120	64	ADVIA-120		14	219.429	18.646	8.50	165.000	274.000
2025-913	8	3 ST	31	ABBOTT C-D		14	186.571	22.812	12.23	140.000	233.000
2025-913	8	3 ST	84	KX21,300		10	214.400	21.996	10.26	161.000	268.000
2025-913	10	DxH	94	BC DXH 500		109	239.206	12.583	5.26	179.000	299.000
2025-914	2	ACT5 PENTR	73	COULTER AC		32	471.656	17.074	3.62	354.000	590.000
2025-914	2	ACT5 PENTR	78	ABX PENTRA		33	467.182	14.177	3.03	350.000	584.000
2025-914	3	ADVIA 120	64	ADVIA-120		14	453.643	30.001	6.61	340.000	567.000
2025-914	8	3 ST	31	ABBOTT C-D		14	354.143	42.493	12.00	266.000	443.000
2025-914	8	3 ST	84	KX21,300		10	401.400	38.880	9.69	301.000	502.000
2025-914	10	DxH	94	BC DXH 500		109	513.415	19.454	3.79	385.000	642.000
2025-915	2	ACT5 PENTR	73	COULTER AC		32	75.469	4.243	5.62	57.000	94.000

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 18 (24)
DATE : 1/23/2026
TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY   SUB: 70 GENERAL   GRP: 134 PLATELET COUNT NEW

ANALYTE

SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-915	2	ACT5 PENTR	78	ABX PENTRA		33	75.091	3.785	5.04	56.000	94.000
2025-915	3	ADVIA 120	64	ADVIA-120		14	57.071	7.401	12.97	43.000	71.000
2025-915	8	3 ST	31	ABBOTT C-D		14	64.385	5.541	8.61	48.000	80.000
2025-915	8	3 ST	84	KX21,300		10	70.700	7.072	10.00	53.000	88.000
2025-915	10	DxH	94	BC DXH 500		109	73.935	4.595	6.22	55.000	92.000

SPEC: 20 HEMATOLOGY   SUB: 75 BODY FLUID   GRP: 145 BODY FLUID CELL COU.

ANALYTE

SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
159 BF RED CELL COUNT		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}						
2025-951				36	1090.412	116.484	10.68	741.000	1440.000
2025-952				36	1085.353	81.108	7.47	814.000	1357.000
2025-953				36	0.514	0.692	134.49	0	3.000
2025-954				36	0.471	0.652	138.63	0	2.000
2025-955				36	1102.686	102.171	9.27	796.000	1409.000
160 BF WHITE CELL COUNT									
2025-951				35	301.152	31.905	10.59	205.000	397.000
2025-952				35	304.788	31.489	10.33	210.000	399.000
2025-953				35	4.545	2.388	52.54	0	12.000

Participant Summary

MONTH 11 OF YEAR 2025

SPEC: 20 HEMATOLOGY　　　　　SUB: 75 BODY FLUID　　　　　　　　GRP: 145 BODY FLUID CELL COU.

ANALYTE SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
160 BF WHITE CELL COUNT		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}						
2025-954				35	5.235	2.486	47.48	0	13.000
2025-955				35	302.091	32.234	10.67	205.000	399.000

SPE: 30 IMMUNOHEMATOLOGY　　　　　　SUB: 80 ABO-RH　　　　　GRP: 150 ABO-RH

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
083 ABO GROUP													
2025-961				008	008	008	008		005 - AB	76	1	75	0
2025-961				008	008	008	008		008 - O	76	75	75	100
2025-962				005	007	005	007		001 - A	76	1	75	0
2025-962				005	007	005	007		005 - AB	76	74	75	100
2025-962				005	007	005	007		006 - A1B	76	1	75	100
2025-963				001	003	001	003		001 - A	76	74	76	100
2025-963				001	003	001	003		002 - A1	76	2	76	100
2025-964				008	008	008	008		004 - B	76	1	75	0
2025-964				008	008	008	008		008 - O	76	75	75	100
2025-965				004	004	004	004		004 - B	76	75	75	100
2025-965				004	004	004	004		008 - O	76	1	75	0
126 RH TYPE													
2025-961				001	003	001	003		001 - Rh+	76	76	76	100

1/23/2026   PROFICIENCY TESTING SERVICE   PAGE : 20 (24)
LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPE: 30 IMMUNOHEMATOLOGY   SUB: 80 ABO-RH   GRP: 150 ABO-RH

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
126 RH TYPE											
2025-962				001 003	001 003		001 - Rh+	76	76	76	100
2025-963				001 003	001 003		001 - Rh+	76	75	75	100
2025-963				001 003	001 003		004 - Rh-	76	1	75	0
2025-964				003 004	003 004		001 - Rh+	76	1	75	0
2025-964				003 004	003 004		003 - Rh-Du np	76	6	75	100
2025-964				003 004	003 004		004 - Rh-	76	69	75	100
2025-965				001 003	001 003		001 - Rh+	76	75	75	100
2025-965				001 003	001 003		004 - Rh-	76	1	75	0

1/23/2026   PROFICIENCY TESTING SERVICE   PAGE : 21 (24)
                              LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
                          DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPE: 30 IMMUNOHEMATOLOGY   SUB: 90 COOMBS   GRP: 160 Indirect COOMBS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
084 INDIRECT COOMBS											
2025-971				002 002	002 002		001 – NEGATIVE	59	1	58	0
2025-971				002 002	002 002		002 – POSITIVE	59	58	58	100
2025-972				001 001	001 001		001 – NEGATIVE	59	59	59	100
2025-973				001 001	001 001		001 – NEGATIVE	59	59	59	100
2025-974				002 002	002 002		002 – POSITIVE	59	59	59	100
2025-975				001 001	001 001		001 – NEGATIVE	59	58	58	100
2025-975				001 001	001 001		002 – POSITIVE	59	1	58	0

SPE: 30 IMMUNOHEMATOLOGY   SUB: 90 COOMBS   GRP: 165 Direct COOMBS

TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)													
2025-651	001	Poly AHG	001	Gel			002 004		002 – 2+	16	2	16	100
2025-651	001	Poly AHG	001	Gel			002 004		003 – 3+	16	10	16	100
2025-651	001	Poly AHG	001	Gel			002 004		004 – 4+	16	4	16	100
2025-651	001	Poly AHG	002	Tubo		002 004	002 004		001 – Negativo	31	1	30	0
2025-651	001	Poly AHG	002	Tubo		002 004	002 004		002 – 2+	31	25	30	100
2025-651	001	Poly AHG	002	Tubo		002 004	002 004		003 – 3+	31	4	30	100
2025-651	001	Poly AHG	002	Tubo		002 004	002 004		004 – 4+	31	1	30	100
2025-651	002	MnoAnt-IgG	001	Gel		002 004	002 004		003 – 3+	14	12	14	100
2025-651	002	MnoAnt-IgG	001	Gel		002 004	002 004		004 – 4+	14	2	14	100
2025-651	002	MnoAnt-IgG	002	Tubo		002 004			002 – 2+	13	12	13	100

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 22 (24)
DATE : 1/23/2026
TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPE: 30 IMMUNOHEMATOLOGY   SUB: 90 COOMBS   GRP: 165 Direct COOMBS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-651	002 MnoAnt-IgG	002 Tubo		002 004			003 - 3+	13	1	13	100
	179 DIRECT ANTIG(COOMBS)										
2025-652	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	15	15	15	100
2025-652	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	31	30	30	100
2025-652	001 Poly AHG	002 Tubo		001 001	001 001		002 - 2+	31	1	30	0
2025-652	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	14	14	14	100
2025-652	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	13	13	13	100
2025-653	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	16	16	16	100
2025-653	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	31	30	30	100
2025-653	001 Poly AHG	002 Tubo		001 001	001 001		002 - 2+	31	1	30	0
2025-653	002 MnoAnt-IgG	001 Gel		001 001	001 001		001 - Negativo	13	13	13	100
2025-653	002 MnoAnt-IgG	002 Tubo		001 001	001 001		001 - Negativo	13	13	13	100
2025-654	001 Poly AHG	001 Gel			002 004		002 - 2+	16	2	16	100
2025-654	001 Poly AHG	001 Gel			002 004		003 - 3+	16	11	16	100
2025-654	001 Poly AHG	001 Gel			002 004		004 - 4+	16	3	16	100
2025-654	001 Poly AHG	002 Tubo			002 004		002 - 2+	31	20	31	100
2025-654	001 Poly AHG	002 Tubo			002 004		003 - 3+	31	8	31	100
2025-654	001 Poly AHG	002 Tubo			002 004		004 - 4+	31	3	31	100
2025-654	002 MnoAnt-IgG	001 Gel			002 004		003 - 3+	14	11	14	100
2025-654	002 MnoAnt-IgG	001 Gel			002 004		004 - 4+	14	3	14	100
2025-654	002 MnoAnt-IgG	002 Tubo		002 004			002 - 2+	13	11	13	100
2025-654	002 MnoAnt-IgG	002 Tubo		002 004			003 - 3+	13	1	13	100
2025-654	002 MnoAnt-IgG	002 Tubo		002 004			004 - 4+	13	1	13	100
2025-655	001 Poly AHG	001 Gel			002 004		002 - 2+	16	1	16	100
2025-655	001 Poly AHG	001 Gel			002 004		003 - 3+	16	12	16	100
2025-655	001 Poly AHG	001 Gel			002 004		004 - 4+	16	3	16	100

1/23/2026   PROFICIENCY TESTING SERVICE   PAGE : 23 (24)
                     LABORATORY SERVICES PROGRAM   DATE : 1/23/2026
                 DEPARTMENT OF HEALTH OF PUERTO RICO   TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025

SPE: 30 IMMUNOHEMATOLOGY   SUB: 90 COOMBS   GRP: 165 Direct COOMBS

TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-655	001	Poly AHG	002	Tubo				002	004		001 - Negativo	31	1	30	0
2025-655	001	Poly AHG	002	Tubo				002	004		002 - 2+	31	20	30	100
2025-655	001	Poly AHG	002	Tubo				002	004		003 - 3+	31	6	30	100
2025-655	001	Poly AHG	002	Tubo				002	004		004 - 4+	31	4	30	100
2025-655	002	MnoAnt-IgG	001	Gel				002	004		003 - 3+	14	11	14	100
2025-655	002	MnoAnt-IgG	001	Gel				002	004		004 - 4+	14	3	14	100
2025-655	002	MnoAnt-IgG	002	Tubo		002	004				002 - 2+	13	12	13	100
2025-655	002	MnoAnt-IgG	002	Tubo		002	004				003 - 3+	13	1	13	100

SPE: 30 IMMUNOHEMATOLOGY   SUB: 100 COMPATIBILITY TESTING   GRP: 170 COMPATIBILITY TEST.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH		REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
085 COMPATIBIL. TESTING														
2025-981				001	001	001	001			001 - COMPATIBLE	38	38	38	100
2025-982				001	001	001	001			001 - COMPATIBLE	38	38	38	100
2025-983				002	002	002	002			002 - INCOMPATIB	38	38	38	100
2025-984				002	002	002	002			001 - COMPATIBLE	38	1	37	0
2025-984				002	002	002	002			002 - INCOMPATIB	38	37	37	100
2025-985				001	001	001	001			001 - COMPATIBLE	38	38	38	100

1/23/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 24 (24)
DATE : 1/23/2026
TIME : 11:26:54

Participant Summary

MONTH 11 OF YEAR 2025